Cargando…

Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS: PROs were assessed on the European Organization for Research and Treatment of Cancer Qualit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, Van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John, Weisel, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078427/ https://www.ncbi.nlm.nih.gov/pubmed/33326255 http://dx.doi.org/10.1200/JCO.20.01370

Ejemplares similares

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
por: Facon, T., et al.
Publicado: (2023)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
por: Weisel, K., et al.
Publicado: (2023)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
por: Facon, T., et al.
Publicado: (2022)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Los maias
por: Queirós, Eça de, 1845-1900
Publicado: (1972)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Popat, R, et al.
Publicado: (2022)

Integrating genome assemblies with MAIA
por: Nijkamp, Jurgen, et al.
Publicado: (2010)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

The Multidimensional Assessment of Interoceptive Awareness (MAIA)
por: Mehling, Wolf E., et al.
Publicado: (2012)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
por: Iida, Shinsuke, et al.
Publicado: (2021)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2023)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients
por: Belch, Andrew, et al.
Publicado: (2020)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

P05.61. The multidimensional assessment of interoceptive awareness (MAIA)
por: Mehling, WE, et al.
Publicado: (2012)

The Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2)
por: Mehling, Wolf E., et al.
Publicado: (2018)

First person – Ivana María Gómez and Maia Abigail Rodríguez
Publicado: (2019)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma
por: Gries, Katharine S., et al.
Publicado: (2020)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
por: Avet-Loiseau, Hervé, et al.
Publicado: (2021)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Psychometric properties of the multidimensional assessment of interoceptive awareness (MAIA) in a Chilean population
por: Valenzuela-Moguillansky, Camila, et al.
Publicado: (2015)

Interpreting MAIA Microperimetry Using Age- and Retinal Loci-Specific Reference Thresholds
por: Charng, Jason, et al.
Publicado: (2020)

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
por: Weisel, K., et al.
Publicado: (2022)

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
por: Dimopoulos, MA, et al.
Publicado: (2022)

Reference Clinical Database for Fixation Stability Metrics in Normal Subjects Measured with the MAIA Microperimeter
por: Morales, Marco U., et al.
Publicado: (2016)

MAIA—A machine learning assisted image annotation method for environmental monitoring and exploration
por: Zurowietz, Martin, et al.
Publicado: (2018)

Investigating Multidimensional Interoceptive Awareness in a Japanese Population: Validation of the Japanese MAIA-J
por: Shoji, Masayasu, et al.
Publicado: (2018)

Intersession test–retest variability of 10-2 MAIA microperimetry in fixation-threatening glaucoma
por: Wong, Evan N, et al.
Publicado: (2017)

Psychometric Properties of the Multidimensional Assessment of Interoceptive Awareness (MAIA) Questionnaire in Colombian University Students
por: Montoya-Hurtado, Olga, et al.
Publicado: (2023)

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
por: Jakubowiak, Andrzej J, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Translation and validation of a Bahasa Malaysia (Malay) version of the Multidimensional Assessment of Interoceptive Awareness (MAIA)
por: Todd, Jennifer, et al.
Publicado: (2020)

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
por: Knop, Stefan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uh88otq6tpemj07jf4mclhvr65